Kara M. Ruicci
Papers
1
Total Citations
15
H-Index
1
About
Kara M. Ruicci is a translational cancer researcher whose work focuses on head and neck squamous cell carcinoma (HNSCC), with a particular emphasis on understanding the differential biology of human papillomavirus (HPV)-positive and HPV-negative disease. Her most notable contribution is a landmark 2018 study that employed high-throughput drug screening across a panel of HNSCC cell lines. This work systematically identified therapeutic agents with preferential activity in either HPV-positive or HPV-negative tumors, providing a critical roadmap for developing more personalized treatment strategies in head and neck cancer. The study, which has garnered 15 citations, directly addressed the pressing clinical need to move beyond one-size-fits-all approaches by exploiting the distinct molecular vulnerabilities of each subtype. By collaborating with a large multidisciplinary team—including surgeons, radiation oncologists, medical oncologists, and basic scientists—Ruicci helped bridge the gap between preclinical discovery and clinical relevance. Her research is foundational for researchers and clinicians seeking to improve outcomes in HNSCC through biomarker-driven therapy selection and represents an important step toward precision oncology in this challenging disease.
Research Focus
Key Achievements
Top Papers
- 1